16.08 USD
-0.45 (-2.72%)
16.1244 USD
+0.04 (+0.28%)
We assign a fundamental rating of 3 out of 10 to SGRY. SGRY was compared to 100 industry peers in the Health Care Providers & Services industry. SGRY has a medium profitability rating, but doesn't score so well on its financial health evaluation. SGRY has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SGRY had positive earnings in the past year.
SGRY had a positive operating cash flow in the past year.
In the past 5 years SGRY always reported negative net income.
SGRY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
SGRY has a Return On Assets (-2.17%) which is comparable to the rest of the industry.
With a Return On Equity value of -9.97%, SGRY perfoms like the industry average, outperforming 42.00% of the companies in the same industry.
SGRY has a Return On Invested Capital (5.63%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for SGRY is below the industry average of 9.44%.
The last Return On Invested Capital (5.63%) for SGRY is above the 3 year average (5.03%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -9.97% | ||
| ROIC | 5.63% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
Looking at the Operating Margin, with a value of 15.96%, SGRY belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
In the last couple of years the Operating Margin of SGRY has remained more or less at the same level.
SGRY has a Gross Margin (26.57%) which is in line with its industry peers.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% |
OM growth 3Y3.69%
OM growth 5Y1.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SGRY is destroying value.
SGRY has about the same amout of shares outstanding than it did 1 year ago.
SGRY has more shares outstanding than it did 5 years ago.
SGRY has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.78, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.78, SGRY is not doing good in the industry: 76.00% of the companies in the same industry are doing better.
The Debt to FCF ratio of SGRY is 18.37, which is on the high side as it means it would take SGRY, 18.37 years of fcf income to pay off all of its debts.
SGRY has a Debt to FCF ratio of 18.37. This is comparable to the rest of the industry: SGRY outperforms 41.00% of its industry peers.
SGRY has a Debt/Equity ratio of 2.00. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.00, SGRY is not doing good in the industry: 73.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Altman-Z | 0.78 |
ROIC/WACC0.64
WACC8.74%
2.3 Liquidity
SGRY has a Current Ratio of 1.88. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.88, SGRY is doing good in the industry, outperforming 77.00% of the companies in the same industry.
A Quick Ratio of 1.72 indicates that SGRY should not have too much problems paying its short term obligations.
The Quick ratio of SGRY (1.72) is better than 72.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.02%.
Looking at the last year, SGRY shows a quite strong growth in Revenue. The Revenue has grown by 10.16% in the last year.
The Revenue has been growing by 11.20% on average over the past years. This is quite good.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)10.16%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
3.2 Future
Based on estimates for the next years, SGRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.89% on average per year.
Based on estimates for the next years, SGRY will show a small growth in Revenue. The Revenue will grow by 7.88% on average per year.
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.62, which indicates a rather expensive current valuation of SGRY.
Based on the Price/Earnings ratio, SGRY is valued a bit cheaper than the industry average as 69.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.76, SGRY is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 21.45, the valuation of SGRY can be described as rather expensive.
SGRY's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.96, SGRY is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.62 | ||
| Fwd PE | 21.45 |
4.2 Price Multiples
78.00% of the companies in the same industry are more expensive than SGRY, based on the Enterprise Value to EBITDA ratio.
82.00% of the companies in the same industry are more expensive than SGRY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.72 | ||
| EV/EBITDA | 8.45 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
5. Dividend
5.1 Amount
No dividends for SGRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.08
-0.45 (-2.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners80.74%
Inst Owner Change5.61%
Ins Owners1.11%
Ins Owner Change-0.09%
Market Cap2.08B
Revenue(TTM)3.29B
Net Income(TTM)-172.50M
Analysts81.11
Price Target26.52 (64.93%)
Short Float %18.33%
Short Ratio8.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.56%
Min EPS beat(2)-23.03%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.06%
Min EPS beat(4)-24.34%
Max EPS beat(4)24.15%
EPS beat(8)5
Avg EPS beat(8)2.45%
EPS beat(12)9
Avg EPS beat(12)185.54%
EPS beat(16)10
Avg EPS beat(16)107.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.63%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)-0.71%
Revenue beat(16)5
Avg Revenue beat(16)-1.03%
PT rev (1m)-16.67%
PT rev (3m)-17.1%
EPS NQ rev (1m)-35.27%
EPS NQ rev (3m)-34.03%
EPS NY rev (1m)-24.86%
EPS NY rev (3m)-23.71%
Revenue NQ rev (1m)-6.83%
Revenue NQ rev (3m)-6.71%
Revenue NY rev (1m)-1.84%
Revenue NY rev (3m)-1.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.62 | ||
| Fwd PE | 21.45 | ||
| P/S | 0.63 | ||
| P/FCF | 10.72 | ||
| P/OCF | 7.38 | ||
| P/B | 1.2 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.45 |
EPS(TTM)0.78
EY4.85%
EPS(NY)0.75
Fwd EY4.66%
FCF(TTM)1.5
FCFY9.33%
OCF(TTM)2.18
OCFY13.56%
SpS25.43
BVpS13.38
TBVpS-26.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.17% | ||
| ROE | -9.97% | ||
| ROCE | 7.13% | ||
| ROIC | 5.63% | ||
| ROICexc | 5.63% | ||
| ROICexgc | 18.62% | ||
| OM | 15.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% | ||
| FCFM | 5.9% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.79%
ROICexgc growth 5Y0.89%
ROICexc growth 3Y5%
ROICexc growth 5Y3.38%
OM growth 3Y3.69%
OM growth 5Y1.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Debt/EBITDA | 5.13 | ||
| Cap/Depr | 58.67% | ||
| Cap/Sales | 2.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 41.8% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z | 0.78 |
F-Score4
WACC8.74%
ROIC/WACC0.64
Cap/Depr(3y)68.15%
Cap/Depr(5y)61.6%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue 1Y (TTM)10.16%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
EBIT growth 1Y17.2%
EBIT growth 3Y15.99%
EBIT growth 5Y12.78%
EBIT Next Year41.53%
EBIT Next 3Y20.05%
EBIT Next 5YN/A
FCF growth 1Y32.24%
FCF growth 3Y92.37%
FCF growth 5Y30.31%
OCF growth 1Y18.29%
OCF growth 3Y51.02%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SGRY.
Can you provide the valuation status for SURGERY PARTNERS INC?
ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for SGRY stock?
The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 20.62 and the Price/Book (PB) ratio is 1.2.
Is the dividend of SURGERY PARTNERS INC sustainable?
The dividend rating of SURGERY PARTNERS INC (SGRY) is 0 / 10 and the dividend payout ratio is 0%.